FXYD3 Expression in Gliomas and its Clinicopathological Significance
2009 (English)In: Oncology Research, ISSN 0965-0407, Vol. 18, no 4, 133-139 p.Article in journal (Refereed) Published
FXYD3, interacting with Na+/K+-ATPase, is considered a cell surface regulator modulating the function of ion pumps and ion channels. The FXYD3 gene was originally cloned from murine mammary tumors and then from human breast tumors. However, no study of FXYD3 has been carried out in gliomas; therefore, we examined FXYD3 expression in gliomas and its clinicopathological significance. FXYD3 expression was immunohistochemically examined in 71 primary gliomas, along with 37 matched adjacent normal brain samples and 8 recurred gliomas. The frequency of strong FXYD3 expression was higher in the primary tumors in either unmatched (p = 0.046) or matched cases (p = 0.02), compared to normal brain tissue. FXYD3 expression was significantly more increased in females than males (p = 0.01), and in multiple site gliomas than single sites (p = 0.02). There was no difference of FXYD3 expression regarding age, tumor location, size, histological type, and tumor grade (p greater than 0.05). The results suggest that FXYD3 expression may be involved in glioma development, especially in multiple gliomas and female patients.
Place, publisher, year, edition, pages
2009. Vol. 18, no 4, 133-139 p.
Glioma; FXYD3; Immunohistochemistry
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-52870DOI: 10.3727/096504009790217380ISI: 000272875000001OAI: oai:DiVA.org:liu-52870DiVA: diva2:285787